Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01157065 · ClinicalTrials.gov registry record · Phase 2
Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
A Phase 2 study of Exudative Age-Related Macular Degeneration, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 1
- Study location
NCT01157065 is a Phase 2 study of Exudative Age-Related Macular Degeneration that has completed, run by Alcon Research. The registered enrollment target is 99 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01157065, a Phase 2 study of Exudative Age-Related Macular Degeneration, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
Conditions Studied
Interventions
- DRUG Ranibizumab
- DRUG AL-78898A
Study Locations (1)
Texas
- Contact Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01157065
The ClinicalTrials.gov registry entry for NCT01157065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Exudative Age-Related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab is the first listed.
NCT01157065 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01157065 about?
NCT01157065 is a clinical study titled "Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration". The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.
What is the current status of trial NCT01157065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2011-06. Estimated completion is 2012-04.
What conditions does trial NCT01157065 study?
This clinical trial studies the following conditions: Exudative Age-Related Macular Degeneration.
What interventions are being tested in trial NCT01157065?
The interventions under investigation include: Ranibizumab (DRUG), AL-78898A (DRUG).
Who is sponsoring clinical trial NCT01157065?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01157065 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exudative Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.